

# JOSEPH M. ELIJAH, PHARM.D, BCOP, BCPS

---

## ACADEMIC APPOINTMENTS

Jul 2024 — Present	<b>Assistant Professor of Pharmacology</b> School of Nursing   Bouvé College of Health Sciences Northeastern University   Boston, MA
Aug 2023 — Present	<b>Assistant Clinical Professor</b> School of Pharmacy and Pharmaceutical Sciences Northeastern University   Boston, MA
Jul 2022 — Jun 2023	<b>Adjunct Clinical Instructor</b> University at Buffalo School of Pharmacy   Buffalo, NY
Jul 2021 — Jun 2022	<b>Adjunct Clinical Instructor</b> University of Michigan College of Pharmacy   Ann Arbor, MI

## CLINICAL APPOINTMENTS

Aug 2023 — Present	<b>Outpatient Clinical Pharmacist Specialist — Gynecologic Oncology</b> Massachusetts General Hospital   Boston, MA
Jul 2022 — Jun 2023	<b>Inpatient Clinical Pharmacist Specialist — Hematology/Oncology</b> Roswell Park Comprehensive Cancer Center   Buffalo, NY
Aug 2022 — Jun 2023	<b>Inpatient Staff Pharmacist</b> Roswell Park Comprehensive Cancer Center   Buffalo, NY
Jun 2021 — Jun 2022	<b>Inpatient Clinical Pharmacist</b> University of Michigan Health   Ann Arbor, MI
Jun 2021 — Jun 2022	<b>Inpatient Staff Pharmacist</b> University of Michigan Health   Ann Arbor, MI

## PHARMACEUTICAL INDUSTRY FELLOWSHIP PROGRAM APPOINTMENTS

Jul 2024 — Present	<b>Fellowship Program Manager</b> Northeastern Pharmaceutical Industry Fellowship Northeastern University   Boston, MA
--------------------	--

## TEACHING EXPERIENCE

Jun 2025	<b>Integrated Science and Therapeutics 6</b> Lecturer – Pain management
Sep 2024 – Present	<b>NRS5117: Advanced Pharmacology</b> Lecturer – Pharmacology of agents across all major organ systems
Oct 2024	<b>Comprehensive Disease Management 2</b> Lecturer – Dermatitis, psoriasis
Oct 2024	<b>Integrated Science and Therapeutics 3</b> Lecturer – Inflammatory bowel disease, rheumatoid arthritis, dermatitis, psoriasis, supportive care in cancer, pain and palliative care
Jun 2024	<b>Comprehensive Disease Management 2</b> Lecturer – Inflammatory bowel disease
Mar 2024 – Apr 2025	<b>Comprehensive Disease Management 4</b> Lecturer – Lung Cancer, colorectal cancer, breast cancer, prostate cancer, supportive care in cancer, pain and palliative care

## **PEER-REVIEWED PUBLICATIONS**

1. Alaklabi S, Roy AM, Zagami P, Chakraborty A, Held N, **Elijah J**, George A, Attwood K, Shaikh SS, Chaudhary LN, Abdou Y, Gandhi S. Real-World Clinical Outcomes With Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer. *JCO Oncol Pract*. 2024;OP2400242.
2. **Elijah J**, Jain P, Holdsworth A, Baron J, Przespolewski E, Attwood K, Wang K, Billias C, Dy G. Trilaciclib use in extensive-stage small cell lung cancer (ES-SCLC): are clinical benefits seen in the real-world setting? *Support Care Cancer*. 2024;32(9):622.
3. **Elijah J**, Puzanov I, Cresanti B, Hamad L, Attwood K, Catalfamo K, Riebandt G. Evaluation of Safety Outcomes Between Nivolumab Regimens with Differing Dosing Patterns. *J Oncol Pharm Pract*. 2024.
4. **Elijah J**, Fitzgerald L, Phan H. Use of CFTR Modulators in Special Populations, Part 1: Pregnancy and Lactation. *Pediatric Pulmonology*. *Pediatr Pulmonol*. 2023;58(12):3377-3385.
5. **Elijah J**, Fitzgerald L, Phan H. Use of CFTR Modulators in Special Populations, Part 2: Severe Lung Disease. *Pediatric Pulmonology*. *Pediatr Pulmonol*. 2023;58(12):3386-3392.
6. Kadouh N, **Elijah J**, Fitzgerald L, Phan H. Use of CFTR Modulators in Special Populations, Part 3: Solid Organ Transplant. *Pediatric Pulmonology*. *Pediatr Pulmonol*. 2023;58(12):3393-3402.
7. **Elijah J**, Jain P, Holdsworth A, Baron J, Przespolewski E, Attwood K, Wang K, Billias C, Dy G. Real World Outcomes of Trilaciclib in ES-SCLC. *J Clin Oncol* 41. 2023 (suppl 16; abstr e20637).
8. **Elijah J**, Schepers A, Krauss J, McDevitt R. Risk Factors for Biliary Toxicity in Patients with Implanted Hepatic Artery Infusion Pumps. *J Oncol Pharm Pract*. 2023;29(8):1915-1920.
9. **Elijah J**, Powell K, Smith M. The Efficacy of Capsaicin on Sleep Quality and Fatigue in Fibromyalgia: A Systematic Review. *J Pain Palliat Care Pharmacother*. 2022; 36(2):112-116.

## **POSTER PRESENTATIONS**

1. **Elijah J**, Puzanov I, Cresanti B, Hamad L, Attwood K, Catalfamo K, Riebandt G. Evaluation of Safety Outcomes Between Nivolumab Regimens with Differing Dosing Patterns. Hematology/Oncology Pharmacy Association (HOPA) 2023 Annual Conference. Phoenix, AZ. Mar 29-Apr 1, 2023.
2. Alaklabi S, **Elijah J**, Gandhi S. Real-World Outcomes of Sacituzumab Govitecan in Metastatic Triple Negative Breast Cancer Patients: A Single Institution Experience. 40<sup>th</sup> Annual Miami Breast Cancer Conference. Miami, FL. Mar 2-5, 2023.
3. **Elijah J**, Schepers A, Krauss J, McDevitt R. Risk Factors for Biliary Toxicity in Patients with Implanted Hepatic Artery Infusion Pumps. Hematology/Oncology Pharmacy Association (HOPA) 2022 Annual Conference. Boston, MA. Mar 30-Apr 2, 2022.
4. **Elijah J**, Schepers A, Krauss J, McDevitt R. Risk Factors for Biliary Toxicity in Patients with Implanted Hepatic Artery Infusion Pumps. Vizient Consortium Pharmacy Network Meeting. Virtual Conference, USA. Jan 13, 2022.

## **ORAL PRESENTATIONS**

1. **Elijah J**. Metastatic Breast Cancer: HER2-low Is A Go! Continuing Education. Roswell Park Comprehensive Cancer Center, Buffalo, NY, April 17, 2023.
2. **Elijah J**. Advanced Cardiac Life Support for Oncology Pharmacists: Restoring the Rhythm at Roswell. Continuing Education. Roswell Park Comprehensive Cancer Center, Buffalo, NY, October 24, 2022.
3. **Elijah J**. Beyond the Horizon — Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Special Populations. Continuing Education. University of Michigan Health, Ann Arbor, MI, June 10, 2022.
4. **Elijah J**, Schepers A, Krauss J, McDevitt R. Risk Factors for Biliary Toxicity in Patients with Implanted Hepatic Artery Infusion Pumps. Great Lakes Pharmacy Resident Conference. West Lafayette, Indiana. April 27-29, 2022.

5. **Elijah J.** Updates in the National Comprehensive Cancer Network Guidelines for Hepatobiliary Cancers. Department of Medical Affairs Town Hall Meeting. AstraZeneca, Gaithersburg, MD, November 4, 2020.
6. **Elijah J.** Review of the Novel Targeted Therapies for Acute Myeloid Leukemia. Seminar presented at the University of Michigan College of Pharmacy, Ann Arbor, MI, September 25, 2020.

## **PROFESSIONAL SERVICE**

Apr 2024 — Present	<b>Faculty Co-advisor of Student Society of Health System Pharmacy</b> School of Pharmacy and Pharmaceutical Sciences Northeastern University   Boston, MA
Jan 2024 — Present	<b>Doctor of Pharmacy Program Admissions Committee Member</b> School of Pharmacy and Pharmaceutical Sciences Northeastern University   Boston, MA
Mar 2022 — Present	<b>Peer-Reviewed Journal Reviewer</b> Journal of Pain and Palliative Care Pharmacotherapy

## **EDUCATION AND TRAINING**

Sep 2024 — Present	<b>Masters in Business Administration</b> D'Amore-McKim School of Business Northeastern University   Boston, MA
Jul 2022 — Jun 2023	<b>PGY2 Hematology/Oncology Pharmacy Residency</b> Roswell Park Comprehensive Cancer Center   Buffalo, NY Residency Program Director: Eugene Przespolewski, PharmD, BCOP
Jun 2021 — Jun 2022	<b>PGY1 Pharmacy Practice Residency</b> University of Michigan Health   Ann Arbor, MI Residency Program Director: John Clark, PharmD, MBA, BCPS
Sep 2017 — Apr 2021	<b>Doctor of Pharmacy with Highest Distinction</b> University of Michigan College of Pharmacy   Ann Arbor, MI
Sep 2013 — Apr 2017	<b>Bachelor of Science in Biological Sciences — <i>Summa Cum Laude</i></b> Oakland University   Rochester Hills, MI

## **LICENSURE AND CERTIFICATION**

Dec 2023 — Present	<b>Board Certified Oncology Pharmacist</b> Board of Pharmacy Specialties
Apr 2023 — Present	<b>Pharmacist License #PH241432</b> Massachusetts Board of Registration in Pharmacy
Dec 2022 — Present	<b>Board Certified Pharmacotherapy Specialist</b> Board of Pharmacy Specialties
Jul 2021 — Jun 2022	<b>Teaching Certificate Program</b> University of Michigan College of Pharmacy   Ann Arbor, MI
May 2022 — Present	<b>Pharmacist License #069067</b> New York Board of Pharmacy
Jul 2021 — Present	<b>Advanced Cardiovascular Life Support Provider</b> American Heart Association
Jun 2021 — Present	<b>Pharmacist License #5302413421</b> Michigan Board of Pharmacy